Advertisement

Archives of Dermatological Research

, Volume 301, Issue 1, pp 99–105 | Cite as

Drug-induced lupus erythematosus

  • Camilla Dalle Vedove
  • Micol Del Giglio
  • Donatella Schena
  • Giampiero GirolomoniEmail author
Review

Abstract

Drug-induced lupus erythematosus (DILE) is defined as a lupus-like syndrome temporally related to continuous drug exposure which resolves after discontinuation of the offending drug. There are currently no standard diagnostic criteria for DILE and the pathomechanisms are still unclear. Similarly to idiopathic lupus, DILE can be diveded into systemic (SLE), subacute cutaneous (SCLE) and chronic cutaneous lupus (CCLE). Systemic DILE is characterized by typical lupus-like symptoms including skin signs, usually mild systemic involvement and a typical laboratory profile with positive antinuclear and anti-histone antibodies, while anti-double strand (ds) DNA and anti-extractable nuclear antigens antibodies are rare. High risk drugs include hydralazine, procainamide and isoniazid. Drug-induced SCLE is very similar to idiopathic SCLE in terms of clinical and serologic characteristic, and it is more common than the systemic form of DILE. Drugs associated with SCLE include calcium channel blockers, angiotensin-converting enzyme inhibitors, interferons, thiazide diuretics and terbinafine. Drug-induced CCLE is very rarely reported in the literature and usually refers to fluorouracile agents or non steroidal anti-inflammatory drugs. Recently, cases of DILE have been reported with anti-TNFα agents. These cases present with disparate clinical features including arthritis/arthralgia, skin rash, serositis, cytopenia and variable laboratory abnormalities. DILE to anti-TNFα agents differs in several ways to classic DILE. The incidence of rashes is higher compared to classical systemic DILE. In most cases of classic DILE visceral involvement is rare, whereas several cases of anti-TNFα DILE with evidence of renal disease have been reported. Low serum complement levels as well as anti-extractable nuclear antigen antibodies and anti-dsDNA antibodies are rarely present in classic DILE, whereas they are reported in half the cases of anti-TNFα DILE; in contrast, anti-histone antibodies are described in classic DILE more often than in anti-TNFα DILE. Recognition of DILE in patients receiving anti-TNFα therapy can be difficult due to the symptoms of their underlying disease. A temporal association (months to years) of the offending drug with characteristic or suggestive symptoms, and resolution of symptoms on drug withdrawal is the best evidence for this diagnosis of DILE.

Keywords

Drug-induced lupus erythematosus Anti-TNFα-induced lupus Antinuclear antibodies (ANA) Anti-histone antibodies Subacute cutaneous drug-induced lupus (SCLE) Drug reactions 

Notes

Conflict of interest statement

The authors have no potential conflict of interest.

References

  1. 1.
    Allanore Y, Sellam J, Batteux F, Job Deslandre C, Weill B, Kahan A (2004) Induction of autoantibody in refractory rheumatoid arthritis patients treated by infliximab. Clin Exp Rheumatol 22:756–758PubMedGoogle Scholar
  2. 2.
    Antonov D, Kazandjieva J, Etugov D, Gospodinov D, Tsankov N (2004) Drug-induced lupus erythematosus. Clin Dermatol 22:157–166. doi: 10.1016/j.clindermatol.2003.12.023 PubMedCrossRefGoogle Scholar
  3. 3.
    Atzeni F, Sarzi-Puttini P, Dell’Acqua D, De Portu S, Cecchini G, Cruini C et al (2006) Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther 8:R3. doi: 10.1186/ar1851 PubMedCrossRefGoogle Scholar
  4. 4.
    Borchers AT, Keen CL, Gershwin ME (2007) Drug-induced lupus. Ann N Y Acad Sci 1108:166–182. doi: 10.1196/annals.1422.019 PubMedCrossRefGoogle Scholar
  5. 5.
    Borg FA, Isenberg DA (2007) Syndromes and complications of interferon therapy. Curr Opin Rheumatol 19:61–66. doi: 10.1097/BOR.0b013e328010c547 PubMedCrossRefGoogle Scholar
  6. 6.
    Caramaschi P, Biasi D, Colombatti M, Pieropan S, Martinelli N, Carletto A et al (2006) Anti-TNFα therapy in rheumatoid arthritis and autoimmunity. Rheumatol Int 26:209–214. doi: 10.1007/s00296-004-0542-1 PubMedCrossRefGoogle Scholar
  7. 7.
    Costa MF, Said NR, Zimmermann B (2007) Drug-induced lupus due to anti-tumor necrosis factor α agents. Semin Arthritis Rheum. Epub ahead of printGoogle Scholar
  8. 8.
    Danchenko N, Satia JA, Anthony MS (2006) Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 15:308–318. doi: 10.1191/0961203306lu2305xx PubMedCrossRefGoogle Scholar
  9. 9.
    D’Auria F, Rovere-Querini P, Giazzon M, Ajello P, Baldissera E, Manfredi A et al (2004) Accumulation of plasma nucleosomes upon treatment with anti-tumor necrosis factor-alpha antibodies. J Intern Med 255:409–418. doi: 10.1111/j.1365-2796.2003.01298.x PubMedCrossRefGoogle Scholar
  10. 10.
    De Bant M, Sibilia J, Le Loet X, Prouzeau S, Fautrel B, Marcelli C, Boucquillard E, Siame JL, Mariette X, Club Rhumatismes et Inflammation (2005) Systemic lupus erythematosus induced by anti-tumor necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 7:R545–R551. doi: 10.1186/ar1715 CrossRefGoogle Scholar
  11. 11.
    De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F (2005) Infliximab, but not etanercept, induces IgM anti-dsDNA antibodies as main antinuclear reactivity: biological and clinical implications in autoimmune arthritis. Arthritis Rheum 52:2192–2201. doi: 10.1002/art.21190 PubMedCrossRefGoogle Scholar
  12. 12.
    Desai SB, Furst DE (2006) Problems encountered during anti-tumor necrosis factor therapy. Best Pract Res Clin Rheumatol 20:757–790. doi: 10.1016/j.berh.2006.06.002 PubMedCrossRefGoogle Scholar
  13. 13.
    Eriksson C, Engstrand S, Sundqvist KG, Rantapaa-Dahlqvist S (2005) Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 64:403–407. doi: 10.1136/ard.2004.024182 PubMedCrossRefGoogle Scholar
  14. 14.
    Fantuzzi F, Del Giglio M, Gisondi P, Girolomoni G (2008) Targeting TNF-α in psoriasis. Exp Opin Ther Targets 12:1085–1096CrossRefGoogle Scholar
  15. 15.
    Ferraccioli G, Mecchia F, Di Poi E, Fabris M (2002) Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis 61:358–361. doi: 10.1136/ard.61.4.358 PubMedCrossRefGoogle Scholar
  16. 16.
    Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N (2004) Infliximab therapy in rheumatoid arthritis and ankylosing apondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther 6:R535–R543. doi: 10.1186/ar1440 PubMedCrossRefGoogle Scholar
  17. 17.
    Gisondi P, Girolomoni G (2007) Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev 6:515–519. doi: 10.1016/j.autrev.2006.12.002 PubMedCrossRefGoogle Scholar
  18. 18.
    Gubinelli E, Cocuroccia B, Girolomoni G (2003) Subacute cutaneous lupus erythematosus induced by nifedipine. J Cutan Med Surg 7:243–246. doi: 10.1007/s10227-002-0122-5 PubMedCrossRefGoogle Scholar
  19. 19.
    Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P, ACCENT I Study Group (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial. Lancet 359:1541–1549. doi: 10.1016/S0140-6736(02)08512-4 PubMedCrossRefGoogle Scholar
  20. 20.
    Hopkinson ND, Doherty M, Powell RJ (1993) The prevalence and incidence of systemic lupus erythematosus in Nottingham, UK 1989–1990. Br J Rheumatol 32:110–115. doi: 10.1093/rheumatology/32.2.110 PubMedCrossRefGoogle Scholar
  21. 21.
    Jimenez S, Cervera R, Font J, Ingelmo M (2003) The epidemiology of systemic lupus erythematosus. Clin Rev Allergy Immunol 25:3–12. doi: 10.1385/CRIAI:25:1:3 PubMedCrossRefGoogle Scholar
  22. 22.
    Johnson AE, Gordon C, Palmer RG, Bacon PA (1995) The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum 38:551–558. doi: 10.1002/art.1780380415 PubMedCrossRefGoogle Scholar
  23. 23.
    Klareskog L, Wajdula J, Yeh P (2005) Low autoantibody and anti-etanercept antibody formation and lack of impact on clinical outcomes after five years of treatment with etanercept in patients with rheumatoid arthritis. Arthritis Rheum 52(Supplement):S543 abstract 881Google Scholar
  24. 24.
    Lopez P, Mozo Gutierrez C, Suarez A (2003) Epidemiology of systemic lupus erythematosus in a northern Spanish population: gender and age influence on immunological features. Lupus 12:860–865. doi: 10.1191/0961203303lu469xx PubMedCrossRefGoogle Scholar
  25. 25.
    Margolis DJ, Hoffstad O, Bilker W (2007) Association or lack association between tetracycline class antibiotics used for acne vulgaris and lupus erythematosus. Br J Dermatol 157:540–546. doi: 10.1111/j.1365-2133.2007.08056.x PubMedCrossRefGoogle Scholar
  26. 26.
    Mor A, Bingham CO, Barisoni L, Lydon E, Belmont HM (2005) Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol 32:740–743PubMedGoogle Scholar
  27. 27.
    Mor A, Pillinger MH, Wortmann RL, Mitnick HJ (2007) Drug-induced arthritic and connective tissue disorders. Sem Arthritis Rheum. Epub ahead of printGoogle Scholar
  28. 28.
    Noel B (2007) Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol 21:17–24. doi: 10.1111/j.1468-3083.2006.01838.x PubMedCrossRefGoogle Scholar
  29. 29.
    Peroni A, Zini A, Braga V, Colato C, Adami S, Girolomoni G (2008) Drug-induced morphea: report of a case induced by balicatib and review of the literature. J Am Acad Dermatol. Epub ahead of printGoogle Scholar
  30. 30.
    Poulalhon N, Begon E, Lebbé C, Lioté F, Lahfa M, Bengoufa D et al (2007) A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol 156:329–336. doi: 10.1111/j.1365-2133.2006.07639.x PubMedCrossRefGoogle Scholar
  31. 31.
    Rahaman A, Isenberg DA (2008) Systemic lupus erythematosus. N Engl J Med 358:929–939. doi: 10.1056/NEJMra071297 CrossRefGoogle Scholar
  32. 32.
    Ramos-Casals M, Brito-Zeron P, Munoz S, Soria N, Galiana D, Bertolaccini L et al (2007) Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86:242–251. doi: 10.1097/MD.0b013e3181441a68 CrossRefGoogle Scholar
  33. 33.
    Rubin RL (2005) Drug-induced lupus. Toxicology 209:135–147. doi: 10.1016/j.tox.2004.12.025 PubMedCrossRefGoogle Scholar
  34. 34.
    Sellam J, Allanore Y, Batteux F, Deslandre CJ, Weill B, Kahan A (2005) Autoantibody induction in patients with refractory spondyloarthropathy treated with infliximab and etanercept. Joint Bone Spine 72:48–52. doi: 10.1016/j.jbspin.2004.03.003 PubMedCrossRefGoogle Scholar
  35. 35.
    Somers EC, Thomas SL, Smeeth L, Schoonen WM, Hall AJ (2007) Incidence of systemic lupus erythematosus in the United Kingdom, 1990–1999. Arthritis Rheum 57:612–618. doi: 10.1002/art.22683 PubMedCrossRefGoogle Scholar
  36. 36.
    Stokes MB, Foster K, Markowitz GS, Ebrahimi F, Hines W, Kaufmen D (2005) Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 20:1400–1406. doi: 10.1093/ndt/gfh832 PubMedCrossRefGoogle Scholar
  37. 37.
    Sturkenboom MC, Meier CR, Jick H, Stricker B (1999) Minocycline and lupuslike syndrome in acne patients. Arch Intern Med 159:493–497. doi: 10.1001/archinte.159.5.493 PubMedCrossRefGoogle Scholar
  38. 38.
    Uetrecht J (2005) Drug-induced lupus erythematosus. In: Kuhn A, Lehmann P, Ruzicka T (eds) Cutaneous lupus erythematosus. Springer, Berlin, pp 117–132CrossRefGoogle Scholar
  39. 39.
    van Rijthoven AVAM, Bijlsma JWJ, Canninga- Van Dijk M, Derksen RHWM, van Roon JAG (2006) Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level. Rheumatology 45:1317–1319. doi: 10.1093/rheumatology/kel227 PubMedCrossRefGoogle Scholar
  40. 40.
    Vasoo S (2006) Drug-induced lupus: an update. Lupus 15:757–761. doi: 10.1177/0961203306070000 PubMedCrossRefGoogle Scholar
  41. 41.
    Via CS, Shustov A, Rus V, Lang T, Nguyen P, Finkelman FD (2001) In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol 167:6821–6826PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Camilla Dalle Vedove
    • 1
  • Micol Del Giglio
    • 1
  • Donatella Schena
    • 1
  • Giampiero Girolomoni
    • 1
    Email author
  1. 1.Section of Dermatology and Venereology, Department of Biomedical and Surgical SciencesUniversity of VeronaVeronaItaly

Personalised recommendations